Header5

The simple corporate scheme behind massive US Brand Drug Prices

My 7-year whistleblower effort
"People Before Profits"

Qui Tam Whistleblower Case Appeals

  • The DOJ recently succeeded in getting both of our qui tam cases dismissed in their entirety by the District Courts, thereby blocking us from pursuing the cases in the public interest
    • The SDNY District Court granted DOJ’s dismissal on July 16, 2019
    • The District of Rhode Island Court (D-RI) granted DOJ’s dismissal on September 27, 2019
  • We are appealing both the District of Rhode Island (D-RI) and Southern District of New York (SDNY) Court decisions regarding these DOJ dismissals

  1. Southern District of New York (SDNY) Appeal to the Second Circuit Court of Appeals:

  1. District of Rhode Island (D-RI) Appeal to the First Circuit Court of Appeals:
    • Brief to be filed in next several months, pending Court schedule

Both appeals based upon: 

  1. Unprecedented and massive alleged public harm apparently not considered by the District Courts
    • D-RI case: $60+ billion and ongoing
      • U.S. multiple sclerosis (MS) drugs rising 10-fold over the past decade-plus
    • SDNY case: $115+ billion and ongoing
      • U.S. cancer, insulins, rheumatoid arthritis and other major brands rising 5-to-10-fold over the past decade-plus
  1. Clear firsthand and repeated admissions by the Department of Justice (DOJ) that it failed to properly investigate these qui tam cases

Including:

  • Failure to investigate central allegations and evidence provided in the qui tam Complaint
  • Failure to pursue major firsthand insider witnesses provided in the qui tam Complaint
  • Failure to investigate new definitive evidence provided in the qui tam Amended Complaint and other Court documents 
  • Link to the Declaration (Affidavit) of John R. Borzilleri, M.D. regarding DOJ’s admitted failures to investigate
    • Provided to both District Courts, under oath
    •  Discusses voluntary and repeated firsthand DOJ admissions of its failure to properly investigate these qui tam cases
    • Dr. Borzilleri’s Affidavit was not refuted under oath by DOJ
    • Neither Borzilleri, nor his counsel, was permitted to discuss the Affidavit in either District Court prior to it granting DOJ's request for full dismissal of both qui tam cases

 

 

Receive the Latest News

Your email is 100% safe.
Your privacy will be respected.
!
!
Something went wrong. Please check your entries and try again.
Scroll to Top